The 5-year survival of non-small cell lung cancer patients can be as low as 1% in advanced
stages. For patients with resectable disease, the successful choice of preoperative …

We developed a computational platform including machine learning and a mechanistic
mathematical model to find the optimal protocol for administration of platinum-doublet …

Chemotherapy for non-small cell lung cancer (NSCLC) typically involves a doublet regimen
for a number of cycles. For any particular patient, a course of treatment is usually chosen …

The development of computational models for simulating tumor growth and response to
treatment has gained significant momentum during the last few decades. At the dawn of the …

Efficacy of chemotherapeutic treatment continues to vary drastically from patient to patient
because of the complex development and progression of cancer. The standard treatment …

Background: Only 30-40% of non-small cell lung cancer (NSCLC) patients are clinically
sensitive to cisplatin-based chemotherapy. Thus, it is necessary to identify biomarkers for …

The goal of this work was to develop a mathematical model to predict Kaplan–Meier survival
curves for chemotherapy combined with radiation in Non-Small Cell Lung Cancer patients …

Platinum-based combination chemotherapy is the standard treatment for advanced non-
small cell lung cancer (NSCLC). While cisplatin is effective, its use is not curative and …

Significant scientific advances in biomedical research have expanded our knowledge of the
molecular basis of carcinogenesis, mechanisms of cancer growth, and the importance of the …

Cancer is still one of the major causes of death worldwide. Even if its comprehension is
improving continuously, the complexity and heterogeneity of this group of diseases …